DXB
Dimerix Ltd
Biotechnology
·
Healthcare
3
comments
3
fund managers
past 90 days
About Dimerix Ltd
Dimerix Ltd. is an Australian biopharmaceutical company headquartered in Melbourne, established in 1975. The firm focuses on the research and development of novel therapeutic candidates. Pipeline assets include DMX-200, currently under development for renal and respiratory indications, and DMX-700, a pre-clinical asset targeting Chronic Obstructive Pulmonary Disease (COPD).
Commentary Volume
3
Comments
3
Fund managers
0
Past 90 days
SOURCE
ACTION
COMMENT PREVIEW
FUND MANAGER
DATE
Loading...
.
​Loading...
Loading...
Loading...
Loading...
Source: Ipsum Capital Q4 Quarterly Letter · Published 14 March 2025
Report a problem
Loading...
.
Loading...
Loading...
Loading...
Loading...
§ Important Notice
The entries below are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Commentary
Sector
Healthcare
Market cap
$123M
Fund managers
3 managers
First covered
31 May 2025
Last updated
30 Apr 2026
Company Details
Related Themes
ic
Ipsum Capital
6 comments
ic
Amet Funds
4 comments
ic
Dolor
3 comments
Top Investors Covering MIN
§ Reminder
The entries above are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Frequently asked questions about Dimerix Ltd (ASX:DXB)
Frequently asked questions
Who is investing in Dimerix Ltd (ASX:DXB)?
Fund managers including Pengana Capital Group, Yarra Capital Management and SG Hiscock & Company have invested in Dimerix Ltd (ASX:DXB).
What is the short interest in Dimerix Ltd (ASX:DXB)?
The short interest in Dimerix Ltd (ASX:DXB) is 0.15% which makes it the 373rd most shorted stock on the ASX. Of the 600.4M shares that Dimerix Ltd has on issue, 877.1K have been sold short.
What does Dimerix Ltd (ASX:DXB) do?
Dimerix Ltd. is an Australian biopharmaceutical company headquartered in Melbourne, established in 1975. The firm focuses on the research and development of novel therapeutic candidates. Pipeline assets include DMX-200, currently under development for renal and respiratory indications, and DMX-700, a pre-clinical asset targeting Chronic Obstructive Pulmonary Disease (COPD).
Loading...